DAVID W GRYSKA
CIK 1202335 · Executive Vice President, CFO · last filed 2026-06-02
DAVID W GRYSKA is an Executive Vice President, CFO who has filed 116 SEC Form 4 insider transactions across 10 companies since 2007. The most recent filing, for FBRX, was dated Jun 2, 2026. Across all open-market trades the lifetime net is −$23.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $3.7M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$3.72M
10
116
-$23.62M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| FBRX | Director | 148,514 | $17.56 | $2.61M | $0 | 6 | 2026-06-02 |
| Definium Therapeutics, Inc. (MNMD) Delisted | Director | 19,851 | $15.00 | $297.8K | $38.9K | 5 | 2025-06-16 |
| Seagen Inc. (SGEN) Delisted | Director | 0 | $228.74 | $0 | -$9.71M | 42 | 2023-12-15 |
| AERIE PHARMACEUTICALS INC (AERI) Delisted | Director | 0 | $15.25 | $0 | $0 | 7 | 2022-11-21 |
| GW PHARMACEUTICALS PLC (GWPH) Delisted | Director | — | $218.96 | — | $0 | 2 | 2021-02-24 |
| PDL BIOPHARMA, INC. (PDLI) Delisted | Director | 1,387 | — | — | -$925.8K | 14 | 2020-12-31 |
| INCY | Executive Vice President, CFO | 10,235 | $108.53 | $1.11M | -$9.18M | 17 | 2018-07-18 |
| HYPERION THERAPEUTICS INC (HPTX) Delisted | Director | — | — | — | $0 | 1 | 2013-05-01 |
| CELGENE CORP /DE/ (CELG) Delisted | Chief Financial Officer | 3,763 | — | — | -$3.84M | 20 | 2010-07-15 |
| COTHERIX INC (CTRX) Delisted | Director | — | — | — | $0 | 1 | 2007-01-10 |
Recent Filings
116 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-02 | FBRX | Grant (A) | — | $0 | EDGAR |
| 2025-06-16 | Definium Therapeutics, Inc. (MNMD) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-03-21 | FBRX | Grant (A) | — | $0 | EDGAR |
| 2024-12-05 | Definium Therapeutics, Inc. (MNMD) Delisted | Buy (P) | +2,500 | $17.9K | EDGAR |
| 2024-08-26 | Definium Therapeutics, Inc. (MNMD) Delisted | Buy (P) | +3,500 | $20.9K | EDGAR |
| 2024-08-22 | FBRX | Grant (A) | — | $0 | EDGAR |
| 2024-06-12 | Definium Therapeutics, Inc. (MNMD) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-12-15 | Seagen Inc. (SGEN) Delisted | Disp (D) | −49,003 | -$11.22M | EDGAR |
| 2023-09-20 | FBRX | Grant (A) | — | $0 | EDGAR |
| 2023-08-02 | FBRX | Grant (A) | +148,514 | $150.0K | EDGAR |